---
title: "Krispy Kreme, Inc. Stock 12‑Month Price Target Raised to $4.5, Implies 27% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291431844.md"
description: "Krispy Kreme, Inc.'s average 12-month price target has been raised to $4.50 by five analysts, up from $4.35, implying a 27% upside based on the June 30 closing price. The consensus rating remains 'Hold' among seven covering analysts, comprising two buys, three holds, and two sells."
datetime: "2026-07-01T14:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291431844.md)
  - [en](https://longbridge.com/en/news/291431844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291431844.md)
generator: "portal-rs"
---

# Krispy Kreme, Inc. Stock 12‑Month Price Target Raised to $4.5, Implies 27% Upside

-   According to estimates from 5 analysts, Krispy Kreme, Inc. stock's average price target has risen from $4.35 to $4.5, with forecasts ranging from $3 to $6 per share
-   Based on the Jun. 30 closing price, the updated target implies approximately 27% potential upside
-   Consensus rating remains at “Hold” across 7 covering analysts, with 2 Buys, 3 Holds and 2 Sells

Explore more price target data and ratings for Krispy Kreme, Inc. on the , and track all previous and future analyst recommendations for Krispy Kreme, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [DNUT.US](https://longbridge.com/en/quote/DNUT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Krispy Kreme, Inc. Stock 12‑Month Price Target Cut to $4.34, Implies 27% Upside](https://longbridge.com/en/news/293068373.md)
- [McRae Industries, Inc. declares $0.14 dividend](https://longbridge.com/en/news/298227975.md)
- [Does Toro (TTC) Prioritizing Productivity Gains Hint At A Deeper Shift In Its Profit Playbook?](https://longbridge.com/en/news/298119884.md)
- [Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/298137481.md)
- [What Bollinger Bands Are Saying About Stocks Right Now](https://longbridge.com/en/news/297783105.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**